Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN IN DEXTROSE.
CECLOR CD vs CEFAZOLIN IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic